Optimer Nabs $68M in Stock Sale
San Diego-based Optimer Pharmaceuticals (NASDAQ: OPTR) said today it has raised $67.5 million through a stock offering. The company sold 6 million new shares at $11.25 apiece. The underwriters have an option to buy another 900,000 shares over the next 30 days, which would add more money to the deal. Jefferies & Co., Baird, Canaccord Genuity, JMP Securities, Needham & Co. and ThinkEquity managed the offering. Optimer plans to use the money to commercialize its first product, an antibiotic for ‘C.difficile’ infections, in the U.S. Earlier this week, Optimer said it struck a partnership with Astellas Pharma to market the drug outside the U.S.